Suppr超能文献

Twist激活miR-22以抑制乳腺癌中的雌激素受体α。

Twist activates miR-22 to suppress estrogen receptor alpha in breast cancer.

作者信息

Vesuna Farhad, Lisok Ala, van Diest Paul, Raman Venu

机构信息

Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.

Department of Pathology, University of Utrecht, Utrecht, The Netherlands.

出版信息

Mol Cell Biochem. 2021 Jun;476(6):2295-2306. doi: 10.1007/s11010-021-04065-w. Epub 2021 Feb 13.

Abstract

TWIST1 (Twist) is a basic helix-loop-helix transcription factor that is overexpressed in many cancers and promotes tumor cell invasion, metastasis, and recurrence. In this study, we demonstrate that Twist upregulates expression of microRNA 22 (miR-22) which, in turn, downregulates estrogen receptor alpha (ER) expression in breast cancer. Initial analysis of miR-22 and Twist expression in a panel of breast cancer cell lines showed a direct correlation between Twist and miR-22 levels with miR-22 being highly expressed in ER negative cell lines. Overexpressing Twist caused increased miR-22 levels while downregulating it led to decreased miR-22 expression. To characterize the upstream promoter region of miR-22, we utilized rapid amplification of cDNA ends and identified the transcription start site and the putative promoter region of miR-22. Mechanistically, we determined that Twist, in combination with HDAC1 and DNMT3B, transcriptionally upregulates miR-22 expression by binding to E-boxes in the proximal miR-22 promoter. We also established that miR-22 causes an increase in growth in 3D but not 2D cultures. Importantly, we observed a direct correlation between increased breast cancer grade and Twist and miR-22 expression. We also identified two potential miR-22 binding sites in the 3'-UTR region of ER and confirmed by promoter assays that miR-22 regulates ER expression by binding to both target sites. These results reveal a novel pathway of ER suppression by Twist through miR-22 activation that could potentially promote the ER negative phenotype in breast cancers.

摘要

TWIST1(Twist)是一种碱性螺旋-环-螺旋转录因子,在许多癌症中过表达,促进肿瘤细胞的侵袭、转移和复发。在本研究中,我们证明Twist上调微小RNA 22(miR-22)的表达,而miR-22反过来下调乳腺癌中雌激素受体α(ER)的表达。对一组乳腺癌细胞系中miR-22和Twist表达的初步分析显示,Twist与miR-22水平之间存在直接相关性,miR-22在ER阴性细胞系中高表达。过表达Twist导致miR-22水平升高,而下调Twist则导致miR-22表达降低。为了表征miR-22的上游启动子区域,我们利用cDNA末端快速扩增技术确定了miR-22的转录起始位点和推定的启动子区域。从机制上讲,我们确定Twist与HDAC1和DNMT3B结合,通过与miR-22近端启动子中的E-box结合,转录上调miR-22的表达。我们还发现miR-22在三维培养而非二维培养中促进生长。重要的是,我们观察到乳腺癌分级增加与Twist和miR-22表达之间存在直接相关性。我们还在ER的3'-UTR区域鉴定了两个潜在的miR-22结合位点,并通过启动子分析证实miR-22通过与两个靶位点结合来调节ER表达。这些结果揭示了Twist通过激活miR-22抑制ER的新途径,这可能潜在地促进乳腺癌中的ER阴性表型。

相似文献

1
Twist activates miR-22 to suppress estrogen receptor alpha in breast cancer.
Mol Cell Biochem. 2021 Jun;476(6):2295-2306. doi: 10.1007/s11010-021-04065-w. Epub 2021 Feb 13.
2
Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.
Oncogene. 2012 Jul 5;31(27):3223-34. doi: 10.1038/onc.2011.483. Epub 2011 Nov 7.
8
miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1.
Carcinogenesis. 2014 Feb;35(2):469-78. doi: 10.1093/carcin/bgt330. Epub 2013 Oct 1.

引用本文的文献

1
Long-Chain Fatty Acids Alter Estrogen Receptor Expression in Breast Cancer Cells.
Int J Mol Sci. 2025 Jul 13;26(14):6722. doi: 10.3390/ijms26146722.
2
The Role of the Fox Gene in Breast Cancer Progression.
Int J Mol Sci. 2025 Feb 7;26(4):1415. doi: 10.3390/ijms26041415.
6
Molecular mechanisms of TWIST1-regulated transcription in EMT and cancer metastasis.
EMBO Rep. 2023 Nov 6;24(11):e56902. doi: 10.15252/embr.202356902. Epub 2023 Sep 8.
7
Overexpression of lncRNA-MEG3 inhibits endometrial cell proliferation and invasion via miR-21-5p/DNMT3B/Twist.
Clinics (Sao Paulo). 2023 Jun 29;78:100235. doi: 10.1016/j.clinsp.2023.100235. eCollection 2023.
8
miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism.
Mol Ther. 2023 Jun 7;31(6):1829-1845. doi: 10.1016/j.ymthe.2023.04.019. Epub 2023 May 4.
9
Non-Coding RNAs Modulating Estrogen Signaling and Response to Endocrine Therapy in Breast Cancer.
Cancers (Basel). 2023 Mar 7;15(6):1632. doi: 10.3390/cancers15061632.
10
An Immunocompetent Environment Unravels the Proto-Oncogenic Role of miR-22.
Cancers (Basel). 2022 Dec 19;14(24):6255. doi: 10.3390/cancers14246255.

本文引用的文献

1
Survival advantage and clinicopathological significance of microRNA-22 in cancers: a meta-analysis.
Cancer Manag Res. 2019 Oct 8;11:8855-8868. doi: 10.2147/CMAR.S185124. eCollection 2019.
2
Serum miR-22 Could be a Potential Biomarker for the Prognosis of Breast Cancer.
Clin Lab. 2019 Apr 1;65(4). doi: 10.7754/Clin.Lab.2018.180825.
4
miRBase: from microRNA sequences to function.
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162. doi: 10.1093/nar/gky1141.
6
Estradiol Exposure Differentially Alters Monolayer versus Microtissue MCF-7 Human Breast Carcinoma Cultures.
PLoS One. 2016 Jul 5;11(7):e0157997. doi: 10.1371/journal.pone.0157997. eCollection 2016.
7
Fibroblasts maintained in 3 dimensions show a better differentiation state and higher sensitivity to estrogens.
Toxicol Appl Pharmacol. 2014 Nov 1;280(3):421-33. doi: 10.1016/j.taap.2014.08.021. Epub 2014 Aug 28.
8
Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-α.
Oncogene. 2012 Jul 5;31(27):3223-34. doi: 10.1038/onc.2011.483. Epub 2011 Nov 7.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验